New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTARMS, TDC, MAS, GBCI, UNT, SQI, BIN, ARIA, RL, BRS, FCH, LNKD, EXLP, KROn The Fly: Analyst Upgrade Summary
Bristow Group (BRS) upgraded to Overweight from Equal Weight at Barclays... Exterran Partners (EXLP) upgraded to Outperform from Neutral at Credit Suisse... Felcor Lodging (FCH) upgraded to Outperform from Market Perform at JMP Securities... Kroger (KR) upgraded to Overweight from Neutral at JPMorgan... LinkedIn (LNKD) upgraded to Outperform from Sector Perform at RBC Capital... Masco (MAS) upgraded to Hold from Underweight at KeyBanc... Ralph Lauren (RL) upgraded to Outperform from Market Perform at Wells Fargo... SciQuest (SQI) upgraded to Buy from Hold at Canaccord... Teradata (TDC) upgraded to Buy from Neutral at Longbow... ARIAD (ARIA) upgraded to Buy from Hold at Maxim... Unit Corp. (UNT) upgraded to Outperform from Sector Perform at Howard Weil... Amyris (AMRS) upgraded to Market Perform from Underperform at Cowen... Progressive Waste (BIN) upgraded to Outperform from Neutral at Credit Suisse... Glacier Bancorp (GBCI) upgraded to Buy from Neutral at DA Davidson.
News For BRS;EXLP;FCH;KR;LNKD;MAS;RL;SQI;TDC;ARIA;UNT;ARMS;BIN;GBCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTTDCOn the Fly: Analyst Initiation Summary
Subscribe for More Information
10:02 EDTLNKDOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AmSurg (AMSG) upgraded to Overweight from Neutral at Piper Jaffray... Anglo American (AAUKY) upgraded to Neutral from Sell at Goldman... Autobytel (ABTL) upgraded to Buy from Hold at Ascendiant... Charles River Labs (CRL) upgraded to Outperform from Market Perform at William Blair... Chesapeake (CHK) upgraded to Outperform from Neutral at Credit Suisse... CubeSmart (CUBE) upgraded to Buy from Neutral at SunTrust... Cypress Semiconductor (CY) upgraded to Neutral from Underweight at JPMorgan... DreamWorks Animation (DWA) upgraded to Overweight from Neutral at Piper Jaffray... E-Trade (ETFC) upgraded at Credit Suisse... Kate Spade (KATE) upgraded to Buy from Neutral at Mizuho... LinkedIn (LNKD) upgraded to Strong Buy from Market Perform at Raymond James... Matthews (MATW) upgraded to Outperform from Neutral at Macquarie... Meridian Bioscience (VIVO) upgraded to Buy from Hold at Craig-Hallum... Michael Kors (KORS) upgraded to Buy from Neutral at Mizuho... NIC Inc. (EGOV) upgraded to Hold from Sell at Maxim... Natural Grocers (NGVC) upgraded to Overweight from Neutral at Piper Jaffray... Nucor (NUE) upgraded to Buy from Neutral at Goldman... ResMed (RMD) upgraded to Buy from Hold at Needham... Smith & Wesson (SWHC) upgraded to Buy from Neutral at Dougherty... Ternium (TX) upgraded to Neutral from Sell at Goldman... Union Pacific (UNP) upgraded to Buy from Hold at BB&T... ZAGG (ZAGG) upgraded to Buy from Hold at Craig-Hallum... lululemon (LULU) upgraded to Overweight from Neutral at JPMorgan.
09:22 EDTLNKDLinkedIn upgraded to Strong Buy from Market Perform at Raymond James
Subscribe for More Information
06:45 EDTLNKDLinkedIn upgraded to Strong Buy from Market Perform at Raymond James
Subscribe for More Information
January 22, 2015
16:27 EDTTDCTeradata initiated with a Market Perform at Cowen
Target $46.
07:38 EDTARIAARIAD appoints DesRosier as Chief Legal and Administrative Officer
Subscribe for More Information
January 21, 2015
09:02 EDTSQISciQuest names Beth Hendriks as Chief Technology Officer
SciQuest (SQI) announced that EMC (EMC) executive Beth Hendriks will be joining the company as its new chief technology officer. In this role, she will be responsible for enhancing the breadth and depth of the SciQuest Spend Management Suite while accelerating technology and user experience innovation. Hendriks joins SciQuest from EMC, where she served as senior director of engineering.
January 20, 2015
07:36 EDTARIAARIAD says EC endorses final opinion adopted by CHMP on Iclusig
Subscribe for More Information
January 16, 2015
10:06 EDTFCHBofA/Merrill real estate analysts to hold an analyst/industry conference call
U.S. Real Estate Analyst Spector, along with EMEA Real State Analyst Bessell, HK/China Real Estate Analyst Ngai and ASEAN Real Estate Analyst Chua, discuss key trends in Global Property/Real Estate in 2015 on an Analyst/Industry conference call to be held on January 20 at 8 am.
January 15, 2015
05:55 EDTKRSupermarkets upgraded to Neutral from Cautious at Goldman Sachs
Subscribe for More Information
January 14, 2015
10:27 EDTLNKDFacebook, Google seen at front of 'multi-year' positive run for Internet stocks
Subscribe for More Information
09:30 EDTKRKroger Q4 trends ahead of expectations, says Cleveland Research
Subscribe for More Information
07:20 EDTARIAARIAD sees product revenues reaching over $400M in 2018
For 2014, sees product and license revenue at $100M, R&D expenses $120M. For 2015, plans to accelerate Iclusig sales in U.S. and Europe, initiate key Iclusig trials, secure broad partnership for brigatinib, file for Iclusig approval in Japan with Otsuka, file IND for new development candidate AP32788. Comments from slides that will be presented at the JP Morgan Healthcare Conference.
January 13, 2015
07:40 EDTARIAARIAD reports net sales of Iclusig of approx. $55M for year ended Dec. 31
Subscribe for More Information
07:39 EDTARIAARIAD announces key strategic objectives for 2015
ARIAD Pharmaceuticals announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These objectives are focused on expanded commercial, research and development, and new business development initiatives that together are expected to lead ARIAD to sustained profitability beginning in 2018 without the need for additional equity capital to fund its operations. ARIAD management will provide detail on its corporate strategy for the next several years. This new focus includes: Expanding the global commercial opportunity for Iclusig through a Japan/Asia partnership with Otsuka Pharmaceutical Co., Ltd., and additional regional distributorships, Leveraging its existing commercial infrastructure and investment, particularly in Europe, Securing a broad co-development and co-commercialization partnership for brigatinib, or AP26113, that will accelerate the study of brigatinib in earlier lines of treatment, Investing in three randomized clinical trials to evaluate Iclusig in earlier lines of treatment and potentially to expand its addressable market, Advancing its new development candidate, AP32788, into the clinic, and Achieving sustained profitability in 2018 by reaching global product revenue of more than $400M. Three key Iclusig clinical trials will begin in 2015 including a randomized, Phase 3 trial in patients with chronic-phase CML who have experienced failure after imatinib therapy. This second-line, global trial will evaluate two doses of Iclusig vs. the standard dose of nilotinib. The primary endpoint of the trial will be major molecular response by 12 months. The trial is expected to open to patient enrollment in the second half of 2015 and will be integral to potentially expanding Iclusig into earlier lines of treatment. We expect that approximately 500 patients will be enrolled in this trial. ARIAD says "In a major strategic shift for ARIAD, we expect to secure a broad partnership in 2015 to co-develop and co-commercialize brigatinib. In doing so, we will continue to leverage our existing infrastructure and capabilities, allowing us to accelerate the start of a randomized, first-line trial of brigatinib vs. crizotinib. A partnership will also provide for the exploration of new combination therapies in lung cancer that include brigatinib potentially with other approved and unapproved medicines." The company comments, "We expect to achieve profitability in 2018 through revenue growth and strategic partnerships over the next three years. This includes Iclusig revenue growth in the U.S. and in Europe, as well as Iclusig revenue from Japan and new geographies. We also anticipate increased cash flow from brigatinib revenue and partnership payments during this time period. We expect approval of Iclusig in Canada and Israel in 2015 and in Japan in 2016."
07:03 EDTTDCTeradata acquires Appoxee for undisclosed amount
Subscribe for More Information
06:33 EDTTDCTeradata set to acquire Appoxee for about $20M, WSJ reports
Teradata (TDC) will buy Appoxee, a Tel Aviv-based mobile-marketing-automation startup, for around $20M, The Wall Street Journal reports, citing two sources. Teradata rival IBM (IBM) acquired Xtify, a mobile-marketing company, in 2013. Reference Link
January 12, 2015
07:35 EDTTDCNational Retail Federation to hold a trade show
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use